Opendata, web and dolomites


Leveraging Pharmaceutical Sciences and Structural Biology Training to develop 21st Century Vaccines

Total Cost €


EC-Contrib. €






 PHA-ST-TRAIN-VAC project word cloud

Explore the words cloud of the PHA-ST-TRAIN-VAC project. It provides you a very rough idea of what is the project "PHA-ST-TRAIN-VAC" about.

guarantee    syncytial    acute    innovative    formulation    disease    equip    entrepreneurship    century    expanding    partnership    intersectoral    vac    purpose    generation    66    risk    population    respiratory    team    meet    21st    pharmaceutical    virus    rsv    elderly    pharmacy    stage    patient    record    invasive    deaths    leader    vaccinologists    immunisation    immunology    st    33    pregnant    protect    infectious    multidisciplinary    translatable    eid    serious    ing    vaccines    age    groups    engineering    training    vaccine    million    world    millions    train    university    annually    group    biology    saving    lives    pha    ustrath    immunomodulation    hospitalisations    gbs    strathclyde    biomedical    199    skills    proven    diseases    pose    lower    track    born    structural    women    influenza    tools    international    infections    health    globally    global    tract    eliminate    ageing    teams    appropriate    cross    streptococcus    fit    infants    sciences    gsk   

Project "PHA-ST-TRAIN-VAC" data sheet

The following table provides information about the project.


Organization address
address: Richmond Street 16
postcode: G1 1XQ

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website
 Total cost 1˙062˙698 €
 EC max contribution 1˙062˙698 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2015
 Funding Scheme MSCA-ITN-EID
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2020-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF STRATHCLYDE UK (GLASGOW) coordinator 546˙575.00
2    GLAXOSMITHKLINE VACCINES SRL IT (SIENA) participant 516˙122.00


 Project objective

Immunisation is one of the most cost-effective and proven tools to control and eliminate infectious diseases, saving millions of lives each year, yet key challenges remain in order to guarantee the future health of the expanding and ageing global population. For example, effective vaccines are still required for Respiratory Syncytial Virus (RSV) and Group B Streptococcus (GBS), both of which cause significant hospitalisations globally each year. RSV is a common cause of respiratory disease among all age groups; annually it results in an estimated 33.8 million acute lower respiratory tract infections (resulting in 66,000-199,000 deaths) and among the elderly, it results in as many hospitalisations as influenza. Group B Streptococcus (GBS) infections also pose a serious risk; GBS is a leading cause of invasive infections in pregnant women, new-born infants, and the elderly. To meet the challenge of developing fit-for-purpose, age-appropriate vaccines against these disease targets, this EID will bring together two cross-sector, world leading teams – GSK Vaccines S.r.L and the University of Strathclyde – with the objective to equip the next generation of vaccinologists with the skills and tools to deliver vaccines for the 21st Century. GSK Vaccines S.r.L is a global leader in vaccine research, development and production and will work in partnership with the vaccine team within USTRATH and the Strathclyde Institute of Pharmacy and Biomedical Sciences, who have an international track-record of translatable and innovative research in immunology, immunomodulation, structural biology, and formulation design and pharmaceutical engineering of vaccine systems. PHA-ST-TRAIN-VAC will deliver a unique, multidisciplinary and intersectoral training programme to develop and equip four early stage researchers with the required skills and entrepreneurship to develop new vaccines to protect against RSV and GBS, in a formulation tailored to the age of the patient.


List of deliverables.
Identification of RSV antigen for alternative vaccination routes Documents, reports 2020-04-08 10:20:48
Bio-distribution of adjuvants and their associated antigen - 1 Documents, reports 2020-04-08 10:20:48
Data management plan Open Research Data Pilot 2020-04-08 10:20:48
Interactions of GBS and RSV antigen and adjuvants Documents, reports 2020-04-08 10:20:48
Key biophysical and physico-chemical attributes of current lipid nanoparticles Documents, reports 2020-04-08 10:20:48
Metabolic factors that contribute to the impaired adaptive immunity in older adults Documents, reports 2020-04-08 10:20:48
Bio-distribution of lipid nanoparticles Documents, reports 2020-04-08 10:20:47
Key physico-chemical attributes of alum, emulsion, liposome and nanoparticle systems shown to be effective as adjuvants Documents, reports 2020-04-08 10:20:47
Model to investigate intracellular ROS, antigen presentation and specific T cell responses Documents, reports 2020-04-08 10:20:48
Identification of self-amplifying RSV RNA construct Documents, reports 2020-04-08 10:20:48
Comparison of cellular uptake in monocyte-derived macrophages and dendritic cells Documents, reports 2020-04-08 10:20:48

Take a look to the deliverables list in detail:  detailed list of PHA-ST-TRAIN-VAC deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHA-ST-TRAIN-VAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHA-ST-TRAIN-VAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

TACT (2020)

Targeted Anti-Cancer Therapies

Read More  

SECRET (2019)

Exploitation of the SECRETory pathway for cancer therapy to address European research

Read More  

PAVax (2020)

A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosa

Read More